ONCOLOGY

ASX Junior Has Early Success With K9 Cancer Trials: Human Trials Await

One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.

IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy

The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.

Could a Loxo Oncology Style Trial, Bring Loxo Style Results for PTX?

Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.

Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.

Thanks for subscribing!

X